Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

S&U delivers steady growth in H1 despite mixed macro backdrop

(Sharecast News) - Specialist lender S&U said on Tuesday that it had delivered steady growth across its motor finance and property bridging divisions despite a mixed macro backdrop. S&U said customer demand remained robust, with credit quality and collections continuing to perform in line with expectations.

Advantage Finance saw net receivables rise 8% year-on-year to £360m, supported by a 6% increase in transaction volumes and stable repayment behaviour, while revenue from its motor finance arm climbed 7% to £54.7m and pre-tax profits grew 6% to £17.2m. Cost of risk remained broadly flat at 6.3%, with the group noting no material impact from recent regulatory developments.

S&U's Aspen Bridging division also delivered growth, with net receivables up 10% to £112m and revenues increasing 12% to £7.5m. Pre-tax profits jumped 18% to £2.6m, driven by improved margins and a more diversified loan book.

The London-listed firm said overall group borrowings rose 5% to £180m, with gearing steady at 63%.

Looking ahead, S&U reaffirmed its full-year guidance and highlighted that it was not exposed to discretionary commission arrangements, distancing itself from potential liabilities linked to the FCA's proposed motor finance redress scheme.

Chairman Anthony Coombs said: "The skies are now brighter for a return to steady sustainable growth than at any time since the pandemic. The difficult regulatory and economic conditions of the past two years have served to prove the resilience of our businesses. Of course, challenges will always remain, but the S&U corporate tanker is undoubtedly turning."

As of 0835 BST, S&U shares were up 3.25% at 1,936p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.